Izvorni znanstveni članak
https://doi.org/10.20471/acc.2018.57.s1.11
Incidental Prostate Cancer in Patients Treated for Benign Prostate Hyperplasia in the Period of 21 Years
Matea Pirša
orcid.org/0000-0002-3838-5423
; Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Ivan Pezelj
; Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Matej Knežević
; Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Borislav Spajić
; Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Igor Tomašković
; Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University, Osijek, Croatia
Ante Reljić
; Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Boris Ružić
; Department of Urology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Sažetak
The aim of this study was to determine the incidence of incidental prostate cancer and its clinical sig-nificance among patients who underwent transurethral prostate resection or transvesical adenomectomy for benign prostate hyperplasia at the Department of Urology in Sestre milosrdnice University Hospital Center from January 1997 to December 2017. A total of 277/4,372 (6.34%) patients from our cohort were diagnosed with incidental prostate cancer (mean age 74.5 years). Due to incomplete data, 12 patents were excluded from further analysis. 44.91% (119/265 patents) of our cohort were stage T1a and 55.09% (146/265) were stage T1b. Clinically significant prostate cancer was found in 168/265 patients (63.40%). When divided into two groups, Gleason score ≤6 (mean age 73.58 years) and Gleason score ≥7 (mean age 75.77 years), the results showed that Gleason score ≥7 patients were significantly older (p=0.0104) and that the tumor extent among patients in this group (mean = 34.58%) was higher than that in Gleason score ≤6 group (mean = 11.11%) (p=0.0169). More than a half of patients in our cohort had T1b stage prostate cancer. We found that 63.4% of carcinomas were clinically significant, with 52/265 (19,62%) patients affected by ISUP grade 4 and 5 cancers. Based on our research, we cannot give any recommendations regarding incidental prostate cancer treatment due to lacking preoperative (PSA, DRE) and follow-up data.
Ključne riječi
Benign prostate hyperplasia; BPH; Incidental prostate cancer; TURP
Hrčak ID:
207903
URI
Datum izdavanja:
1.10.2018.
Posjeta: 1.279 *